D2DR (B-10) Antibody from Santa Cruz Biotechnology, Inc.

Yes, the D2DR (B-10) antibody has been utilized in studies investigating the role of dopamine receptor D2 in various cancers, including breast cancer. For instance, it has been shown that DRD2 expression is downregulated in breast cancer tissues and is associated with patient prognosis, indicating its potential as a therapeutic target (tan2021).

The D2DR (B-10) antibody has been successfully employed in immunohistochemistry to analyze dopamine receptor D2 expression in various tissues, including brain sections and cancer samples. It has been used to assess receptor localization and expression levels in studies involving acute nicotine dependence and glioblastoma (kim2024, vo2022).

The D2DR (B-10) antibody is reactive with mouse, human, and rat tissues, making it suitable for studies involving various model organisms, including mouse models of disease (littrell2012, limanaqi2022).

Yes, studies have demonstrated that modulation of dopamine receptor D2 can influence disease outcomes. For example, dopamine administration was shown to reduce SARS-CoV-2 replication in vitro through downregulation of D2 receptors, highlighting the receptor's role in viral infections (limanaqi2022). Additionally, the antibody has been used to explore the receptor's involvement in acute myeloid leukemia, where its expression correlates with therapeutic responses (aslostov2021).